Olema Widens Loss as Clinical Programs Advance
Cash and securities fell 9% to $461.1 million through June.
Olema Pharmaceuticals (OLMA), a clinical-stage biopharmaceutical company, widened its quarterly net loss about 44% to $63.2 million as clinical-development, research and corporate spending increased.
The higher spending accompanied progress across Olema’s cancer-drug pipeline. The company completed enrollment in the pivotal Phase 3 OPERA-01 trial of palazestrant and now expects top-line results in the first quarter of 2027.
Total operating expenses increased to $67.2 million from $47.9 million a year earlier, producing an operating loss of the same amount. GAAP research-and-development expense rose 32% to $57.8 million, driven by late-stage palazestrant trials, early-stage OP-3136 studies and higher personnel costs. The year-earlier period included a $10.0 million milestone expense tied to Aurigene.
The increase extended beyond trial costs. Non-GAAP R&D expense climbed to $48.9 million from $40.2 million, while related stock-based compensation more than doubled to $8.9 million. GAAP general-and-administrative expense more than doubled to $9.4 million as Olema invested in personnel and infrastructure for late-stage development and anticipated commercial operations, including higher stock compensation and professional fees.
Olema also presented initial Phase 1 monotherapy data for OP-3136, reporting tolerability and evidence of anti-tumor activity across multiple dose levels and tumor types. The company added a clinical collaboration with Bayer to test OP-3136 with darolutamide in metastatic castration-resistant prostate cancer and plans to begin enrollment in the Phase 1b/2 study in the fourth quarter of 2026.
For palazestrant, Olema completed enrollment in a Phase 1b/2 combination study with atirmociclib. The company continued enrolling patients in the Phase 3 OPERA-02 trial and advancing the Phase 1 OP-3136 study.
Cash, cash equivalents and marketable securities declined $44.4 million from the end of 2025, leaving Olema with $461.1 million at June 30 as it moved its lead program toward the OPERA-01 data milestone.